Molecular Oncology Department Metrics

View the grants and publications from the Department of Molecular Oncology.

Grants
  • Regulation of Transcriptional Activation by Protein Disorder
    Sponsor: Univ of South Florida
    PI (MPI):Chen, J.
  • CPTAC Phase III
    Sponsor: Nat Institutes of Health
    PI:Koomen, J.
  • Identification of Non-Coding RNAs to Therapeutically Target Undruggable Pathways in Metastatic Lung Adenocarcinma and Squamous Cell Carcinoma
    Sponsor: Nat Institutes of Health
    PI:Flores, E.
  • Ubiquitination-dependent Regulation of BRAF Function in Melanoma
    Sponsor: Amer Cancer Society
    PI:Wan, L.
  • Targeting the JNK-ITCH Signaling Pathway in Melanoma
    Sponsor: Melanoma Research Alliance (MRA)
    PI:Wan, L.
  • Anti-tumor Potential of Temperature-Sensitive p53 Mutants
    Sponsor: Nat Institutes of Health
    PI (Contact):Chen, J.,PI (MPI):Mann, M.
  • Integrated Program in Cancer and Data Science
    Sponsor: Nat Institutes of Health
    PI (Contact):Cress, D.,PI (MPI):Flores, E.,PI (MPI):Fridley, B.,Co-Leader:Anderson, A.,Co-Leader:Cleveland, J.,Co-Leader:Kanetsky, P.
  • Cancer Research Workforce Development in FAIR Artificial Intelligence and Machine Learning
    Sponsor: Nat Institutes of Health
    PI (Contact):Cress, D.,PI (MPI):Flores, E.,PI (MPI):Fridley, B.
  • Targeting Heme Dependency in Leukemia
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Reuther, G.
  • Incyte/Moffitt Master Research Agreement
    Sponsor: Incyte, Inc.
    PI:Reuther, G.
  • Discovery of p53 inhibitors for reducing toxicity of chemotherapy
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Chen, J.
  • Proteogenomics of Metastatic Heterogeneity and Therapeutic Resistance inLung Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI (Contact):Koomen, J.,CO-PI:Boyle, T.
  • Identifying Metabolic Vulnerabilities in Lung Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Flores, E.,PI (MPI):Haura, E.,Core PI/Director:Fridley, B.,Core PI/Director:Cress, D.,Core PI/Director:Koomen, J.,Project PI:DeNicola, G.,Project PI:Rodriguez, P.,Project PI:Cleveland, J.
  • Direct Control of the human CMG Helicase by Myc and Rb
    Sponsor: Nat Institutes of Health
    PI:Alexandrow, M.
  • Exploring miR-29 in Melanoma Progression and Prevention
    Sponsor: Nat Institutes of Health
    PI:Karreth, F.
  • Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms
    Sponsor: Nat Institutes of Health
    PI:Reuther, G.
  • Propionate metabolism as an essential metabolic adaptation for tumor progression
    Sponsor: Nat Institutes of Health
    PI:Gomes, A.
  • Vitamin B12 supplementation as novel therapeutic strategy to improve cancer-associated outcomes
    Sponsor: Nat Institutes of Health
    PI:Gomes, A.
  • Chromosome 1q ceRNAs in melanoma progression and metastasis
    Sponsor: Nat Institutes of Health
    PI:Karreth, F.
  • Molecular Drivers of Lung Cancer in Hispanics
    Sponsor: Nat Institutes of Health
    PI (Contact):Cress, D.,PI (MPI):Teer, J.
  • Aging as a selective pressure that drives tumor progression
    Sponsor: Nat Institutes of Health
    PI:Gomes, A.
  • Assessing the role of TROLLs as markers of response to chemotherapy in TNBCs
    Sponsor: APIS Assay Technologies - UK
    PI:Flores, E.
  • Elucidating PTEN tumor suppression in melanoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Karreth, F.
  • Engineering inhibitory nanobodies against HPV oncoproteins
    Sponsor: Moffitt Cancer Center
    PI:Binning, J.
  • Biophysical basis for enzyme mediated deglycation in protein repair
    Sponsor: Nat Institutes of Health
    PI:Binning, J.
  • Targeting USP9X-mediated RIT1 stabilization for cancer therapy
    Sponsor: Amer Cancer Society
    PI:Wan, L.
  • Characterizing oncogenic function of ITCH in melanoma
    Sponsor: Nat Institutes of Health
    PI:Wan, L.
  • Mechanisms of age-induced chemotherapeutic resistance in lung cancer
    Sponsor: Amer Lung Assoc
    PI:Gomes, A.
  • Characterization of the Oncogenic Potential of circRNAs in Melanoma
    Sponsor: Nat Institutes of Health
    PI:Karreth, F.
  • NADK as an essential metabolic adaptation of metastatic triple negative breast cancer
    Sponsor: Florida Breast Cancer Foundation
    PI:Gomes, A.
  • Elucidating the Oncogenic Role of sMAF Proteins in Melanoma
    Sponsor: Amer Cancer Society
    PI:Karreth, F.
  • Allosteric Regulation of MDMX by Protein Disorder
    Sponsor: Nat Institutes of Health
    PI (Contact):Chen, J.
  • Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2
    Sponsor: Nat Institutes of Health
    PI:Kissil, J.
  • Dual Source Ion Mobility-Mass Spectrometer
    Sponsor: Nat Institutes of Health
    PI:Koomen, J.
  • Identifying PRC2-independent therapeutic vulnerability of EZH2 in lung cancer
    Sponsor: Moffitt Cancer Center
    PI (Contact):Wan, L.,CO-PI:Gray, J.
  • Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets
    Sponsor: Nat Institutes of Health
    PI:Kissil, J.
  • Establishing the functional differences between variant oncogenic KRAS alleles and identification of allele-selective inhibitors
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Kissil, J.
  • P01 Support Funds
    Sponsor: Moffitt Cancer Center
    PI:Flores, E.
  • Pilot Study of Bladder Cancer Chemo Sensitization by Hypothermia
    Sponsor: Moffitt Cancer Center
    PI (Contact):Chen, J.,PI (MPI):Huang, J.,PI (MPI):Li, R.,PI (MPI):Spiess, P.
  • Deep Learning Module for annotation of murine lung metastases in digital pathology
    Sponsor: Moffitt Cancer Center
    PI (Contact):Flores, E.,PI:Stringfield, O.
  • Exploring the Impact of HSP90 Inhibition on Antigen Presentation and Anti-Tumor Immune Responses
    Sponsor: Nat Institutes of Health
    PI:Jaeger, A.
  • A Chemical Proteomic Strategy for Mapping Codependency Pathways in KRAS-Driven Lung Cancer
    Sponsor: US Army
    PI:Kissil, J.
Publications
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Mahajan S, Majumder A, Stewart PA, Chen YA, Adhikari E, Fang B, Yang Y, Lawrence H, Kinose F, Koomen JM, Haura EB. Deubiquitinase Vulnerabilities Identified through Activity-Based Protein Profiling in Non-Small Cell Lung Cancer. Acs Chem Biol. 2022 Apr.17(4):776-784. Pubmedid: 35311290.
  • Wang B, Wu HH, Abuetabh Y, Leng S, Davidge ST, Flores ER, Eisenstat DD, Leng R. p63, a key regulator of Ago2, links to the microRNA-144 cluster. Cell Death Dis. 2022 Apr.13(4):397. Pubmedid: 35459267. Pmcid: PMC9033807.
  • Gomes AP, Ilter D, Low V, Drapela S, Schild T, Mullarky E, Han J, Elia I, Broekaert D, Rosenzweig A, Nagiec M, Nunes JB, Schaffer BE, Mutvei AP, Asara JM, Cantley LC, Fendt SM, Blenis J. Altered propionate metabolism contributes to tumour progression and aggressiveness. Nat Metab. 2022 Apr.4(4):435-443. Pubmedid: 35361954. Pmcid: PMC9050834.
  • Ampomah PB, Cai B, Sukka SR, Gerlach BD, Yurdagul A, Wang X, Kuriakose G, Darville LNF, Sun Y, Sidoli S, Koomen JM, Tall AR, Tabas I. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. Nat Metab. 2022 Apr.4(4):444-457. Pubmedid: 35361955. Pmcid: PMC9050866.
  • Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
  • Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller JJ, Smith MA, Zhang G, Agarwal S, Creixell M, Meyer BS, Kinose F, Bowers K, Fang B, Stewart PA, Welsh EA, Boyle TA, Meyer AS, Koomen JM, Haura EB. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. Mol Cancer Res. 2022 Apr.20(4):542-555. Pubmedid: 35022314. Pmcid: PMC8983558.
  • Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. Author Correction: ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun. 2022 Mar.13(1):1717. Pubmedid: 35338160. Pmcid: PMC8956651.
  • Karim RM, Yang L, Chen L, Bikowitz MJ, Lu J, Grassie D, Shultz ZP, Lopchuk JM, Chen J, Schönbrunn E. Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain. J Med Chem. 2022 Mar.65(5):4182-4200. Pubmedid: 35191694.
  • Bok I, Angarita A, Douglass SM, Weeraratna AT, Karreth FA. A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities. JID Innov. 2022 Mar.2(2):100076. Pubmedid: 35146482. Pmcid: PMC8819036.
  • Wang Y, Binning JM, Pintilie GD, Chiu W, Amarasinghe GK, Leung DW, Su Z. Cryo-EM analysis of Ebola virus nucleocapsid-like assembly. STAR Protoc. 2022 Mar.3(1):101030. Pubmedid: 34977676. Pmcid: PMC8689349.
  • Andor N, Altrock PM, Jain N, Gomes AP. Tipping Cancer Cells Over the Edge: The Context-Dependent Cost of High Ploidy. Cancer Res. 2022 Mar.82(5):741-748. Pubmedid: 34785577. Pmcid: PMC8898264.
  • Napoli M, Wu SJ, Gore BL, Abbas H, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun. 2022 Feb.13(1):614. Pubmedid: 35105868. Pmcid: PMC8807845.
  • Yaghjyan L, Darville LNF, Cline J, Martinez YC, Rich S, Austin-Datta RJ, Koomen JM, Tworoger SS, Egan KM. Associations of established breast cancer risk factors with urinary estrogens in postmenopausal women. Cancer Causes Control. 2022 Feb.33(2):279-291. Pubmedid: 34988766.
  • Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, Welsh EA, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Cohen MS, Lawrence HR, Rix U. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chem Biol. 2022 Feb.29(2):202-214.e7. Pubmedid: 34329582. Pmcid: PMC8782927.
  • Pandey G, Kuykendall AT, Reuther GW. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer J. 2022 Jan.12(1):13. Pubmedid: 35082276. Pmcid: PMC8792018.
  • Nakamura K, Reid BM, Chen A, Chen Z, Goode EL, Permuth JB, Teer JK, Tyrer J, Yu X, Kanetsky PA, Pharoah PD, Gayther SA, Sellers TA, Lawrenson K, Karreth FA. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer. Am J Hum Genet. 2022 Jan.109(1):116-135. Pubmedid: 34965383. Pmcid: PMC8764204.
  • Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE, Galvez-Reyes J, Kalekar RL, Mulugeta N, Kapner KS, Raghavan MS, Borah AA, Liu N, Väyrynen SA, Costa AD, Ng RWS, Wang J, Hill EK, Ragon DY, Brais LK, Jaeger AM, Spurr LF, Li YY, Cherniack AD, Booker MA, Cohen EF, Tolstorukov MY, Wakiro I, Rotem A, Johnson BE, McFarland JM, Sicinska ET, Jacks TE, Sullivan RJ, Shapiro GI, Clancy TE, Perez K, Rubinson DA, Ng K, Cleary JM, Crawford L, Manalis SR, Nowak JA, Wolpin BM, Hahn WC, Aguirre AJ, Shalek AK. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 Dec.184(25):6119-6137.e26. Pubmedid: 34890551. Pmcid: PMC8822455.
  • Mo Q, Wan L, Schell MJ, Jim H, Tworoger SS, Peng G. Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers (Basel). 2021 Dec.13(24). Pubmedid: 34944787. Pmcid: PMC8699355.
  • Chitsazzadeh V, Nguyen TN, de Mingo Pulido A, Bittencourt BB, Du L, Adelmann CH, Rivera IO, Nguyen KA, Guerra LD, Davis A, Napoli M, Ma W, Davis RE, Rajapakshe K, Coarfa C, Flores ER, Tsai KY. miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGFβR3. J Invest Dermatol. 2021 Dec. Pubmedid: 34890627.
  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Drapela S, Gomes AP. Metabolic requirements of the metastatic cascade. Curr Opin Syst Biol. 2021 Dec.28. Pubmedid: 34693082. Pmcid: PMC8535854.
  • Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 Dec.127(23):4413-4420. Pubmedid: 34358340.
  • El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, Gillies RJ, Yu X, Koomen JM, Yamoah K, Gatenby RA, Ruffell B. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer Res. 2021 Nov.81(21):5477-5490. Pubmedid: 34301759. Pmcid: PMC8563406.
  • Liu CH, Rao Y, Gao D, Wan L, Zhang L. Editorial: Ubiquitin Code: From Cell Biology to Translational Medicine. Front Cell Dev Biol. 2021 Oct.9:791967. Pubmedid: 34778279. Pmcid: PMC8581446.
  • Lee K, Lockhart JH, Xie M, Chaudhary R, Slebos RJC, Flores ER, Chung CH, Tan AC. Deep Learning of Histopathology Images at the Single Cell Level. Front Artif Intell. 2021 Sep.4:754641. Pubmedid: 34568816. Pmcid: PMC8461055.
  • Napoli M, Deshpande AA, Flores ER. The Landmark Discovery That Paved the Way to a Mechanistic Understanding of P53 Gain of Function and Personalized Medicine. Cancer Res. 2021 Sep.81(17):4394-4396. Pubmedid: 34470782.
  • Mecozzi N, Vera O, Karreth FA. Squaring the circle: circRNAs in melanoma. Oncogene. 2021 Sep.40(37):5559-5566. Pubmedid: 34331015. Pmcid: PMC8521449.
  • Aiderus A, Newberg JY, Guzman-Rojas L, Contreras-Sandoval AM, Meshey AL, Jones DJ, Amaya-Manzanares F, Rangel R, Ward JM, Lee SC, Ban KH, Rogers K, Rogers SM, Selvanesan L, McNoe LA, Copeland NG, Jenkins NA, Tsai KY, Black MA, Mann KM, Mann MB. Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression. PLoS Genet. 2021 Aug.17(8):e1009094. Pubmedid: 34398873. Pmcid: PMC8389471.
  • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
  • Shepard A, Hoxha S, Troutman S, Harbaugh D, Kareta MS, Kissil JL. Transcriptional regulation of miR-30a by YAP impacts PTPN13 and KLF9 levels and Schwann cell proliferation. J Biol Chem. 2021 Aug.297(2):100962. Pubmedid: 34265306. Pmcid: PMC8348554.
  • Smalley KSM, Teer JK, Chen YA, Wu JY, Yao J, Koomen JM, Chen WS, Rodriguez-Waitkus P, Karreth FA, Messina JL. A Mutational Survey of Acral Nevi. JAMA Dermatol. 2021 Jul.157(7):831-835. Pubmedid: 33978681. Pmcid: PMC8117064.
  • Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Cell Rep Methods. 2021 Jul.1(3). Pubmedid: 34671754. Pmcid: PMC8525888.
  • Kazi A, Chen L, Xiang S, Vangipurapu R, Yang H, Beato F, Fang B, Williams TM, Husain K, Underwood PW, Fleming JB, Malafa MP, Welsh EA, Koomen JM, Trevino JG, Sebti SM. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Clin Cancer Res. 2021 Jul.27(14):4012-4024. Pubmedid: 33879459. Pmcid: PMC8493485.
  • Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 2021 Jun.12(13):1325. Pubmedid: 34194632. Pmcid: PMC8238243.
  • Karreth FA, Ala U, Provero P, Pandolfi PP. Pseudogenes as Competitive Endogenous RNAs: Target Prediction and Validation. Methods Mol Biol. 2021 Jun.2324:115-129. Pubmedid: 34165712.
  • Xu X, Karreth FA. Pseudogenes as Competitive Endogenous RNAs: Testing miRNA Dependency. Methods Mol Biol. 2021 Jun.2324:131-147. Pubmedid: 34165713.
  • Bok I, Karreth FA. Strategies to Study the Functions of Pseudogenes in Mouse Models of Cancer. Methods Mol Biol. 2021 Jun.2324:287-304. Pubmedid: 34165722.
  • Schild T, McReynolds MR, Shea C, Low V, Schaffer BE, Asara JM, Piskounova E, Dephoure N, Rabinowitz JD, Gomes AP, Blenis J. NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma. Cell Rep. 2021 Jun.35(11):109238. Pubmedid: 34133937.
  • Jinesh GG, Napoli M, Smallin MT, Davis A, Ackerman HD, Raulji P, Montey N, Flores ER, Brohl AS. Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma. Sci Rep. 2021 Jun.11(1):12673. Pubmedid: 34135394. Pmcid: PMC8209049.
  • Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. PLoS One. 2021 Jun.16(6):e0252927. Pubmedid: 34138895. Pmcid: PMC8211232.
  • Ho JS, Di Tullio F, Schwarz M, Low D, Incarnato D, Gay F, Tabaglio T, Zhang J, Wollmann H, Chen L, An O, Chan THM, Hall Hickman A, Zheng S, Roudko V, Chen S, Karz A, Ahmed M, He HH, Greenbaum BD, Oliviero S, Serresi M, Gargiulo G, Mann KM, Hernando E, Mulholland D, Marazzi I, Wee DKB, Guccione E. HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. Elife. 2021 Jun.10. Pubmedid: 34075878. Pmcid: PMC8346284.
  • Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: 34014671.
  • Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, Zhang Z, Xu K, Duan J, He S, Zhang J, Wan L, Liu T, Zhou X, Hung MC, Freeman GJ, Wei W. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021 Jun.81(11):2317-2331.e6. Pubmedid: 33909988. Pmcid: PMC8178223.